Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients
Status:
Unknown status
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The aim of our study is to improve the major molecular remission(MMR) rate and reduce the
cost to treat ph(+) Acute Lymphoblastic Leukemia (ALL) by adjusting chemotherapy regimens and
the dosage of Tyrosine Kinase Inhibitor (TKI). lower the classification of chemotherapy
drugs, lower the side effect brought by which this would be a grateful news for the patients
once this regimens gain a successful result, which is also the final aim of our efforts.